Jolanta Dengler

3.5k total citations
16 papers, 170 citations indexed

About

Jolanta Dengler is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Jolanta Dengler has authored 16 papers receiving a total of 170 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 13 papers in Genetics and 4 papers in Oncology. Recurrent topics in Jolanta Dengler's work include Chronic Myeloid Leukemia Treatments (16 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Jolanta Dengler is often cited by papers focused on Chronic Myeloid Leukemia Treatments (16 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Jolanta Dengler collaborates with scholars based in Germany, France and Argentina. Jolanta Dengler's co-authors include Carla Boquimpani, Jeffrey H. Lipton, Noam Benyamini, Vasily Shuvaev, Anna Turkina, Tomasz Sacha, Naoto Takahashi, Timothy P. Hughes, Nelma Cristina D. Clementino and Sikander Ailawadhi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Jolanta Dengler

15 papers receiving 166 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jolanta Dengler Germany 6 165 140 83 40 20 16 170
Carla Boquimpani Brazil 9 231 1.4× 199 1.4× 108 1.3× 60 1.5× 21 1.1× 29 241
Franck E. Nicolini France 3 180 1.1× 160 1.1× 117 1.4× 15 0.4× 13 0.7× 6 190
Jeffrey Skinner United States 6 188 1.1× 162 1.2× 94 1.1× 40 1.0× 18 0.9× 16 220
Susanne Jung-Munkwitz Germany 4 230 1.4× 207 1.5× 139 1.7× 16 0.4× 22 1.1× 5 235
Vasily Shuvaev Russia 8 232 1.4× 211 1.5× 104 1.3× 54 1.4× 29 1.4× 54 255
Alicia Enrico Argentina 5 198 1.2× 177 1.3× 117 1.4× 33 0.8× 26 1.3× 13 227
Alex Allepuz Switzerland 6 100 0.6× 72 0.5× 36 0.4× 18 0.5× 29 1.4× 15 134
Ulrike Proetel Germany 3 227 1.4× 205 1.5× 139 1.7× 15 0.4× 21 1.1× 4 231
Nadine Pletsch Germany 2 218 1.3× 198 1.4× 131 1.6× 14 0.3× 21 1.1× 2 223
G Rosti Italy 6 107 0.6× 89 0.6× 47 0.6× 15 0.4× 24 1.2× 10 131

Countries citing papers authored by Jolanta Dengler

Since Specialization
Citations

This map shows the geographic impact of Jolanta Dengler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jolanta Dengler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jolanta Dengler more than expected).

Fields of papers citing papers by Jolanta Dengler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jolanta Dengler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jolanta Dengler. The network helps show where Jolanta Dengler may publish in the future.

Co-authorship network of co-authors of Jolanta Dengler

This figure shows the co-authorship network connecting the top 25 collaborators of Jolanta Dengler. A scholar is included among the top collaborators of Jolanta Dengler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jolanta Dengler. Jolanta Dengler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Naumann, Nicole, Johannes Lübke, Volker Hagen, et al.. (2025). Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1. Scientific Reports. 15(1). 26046–26046.
2.
3.
Dengler, Jolanta, et al.. (2022). Treatment-Free Remission in Real-World Chronic Myeloid Leukemia Patients: Insights from German Hematology Practices. Acta Haematologica. 145(6). 603–610. 3 indexed citations
4.
Dengler, Jolanta, Hans Tesch, Kathleen Jentsch‐Ullrich, et al.. (2019). PF418 TREATMENT-FREE REMISSION IN REAL-WORLD CHRONIC MYELOID LEUKEMIA PATIENTS: INSIGHTS FROM GERMAN CLINICAL HEMATOLOGY PRACTICES. HemaSphere. 3(S1). 162–162. 1 indexed citations
5.
Hughes, Timothy P., Carla Boquimpani, Naoto Takahashi, et al.. (2019). ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).. Journal of Clinical Oncology. 37(15_suppl). 7005–7005. 7 indexed citations
6.
7.
Mahon, François‐Xavier, Carla Boquimpani, Naoto Takahashi, et al.. (2019). ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. Clinical Lymphoma Myeloma & Leukemia. 19. S288–S289. 4 indexed citations
8.
Hughes, Timothy P., Carla Boquimpani, Naoto Takahashi, et al.. (2018). ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. Clinical Lymphoma Myeloma & Leukemia. 18. S222–S222. 3 indexed citations
9.
Mahon, François‐Xavier, Carla Boquimpani, Naoto Takahashi, et al.. (2018). Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.. Journal of Clinical Oncology. 36(15_suppl). 7003–7003. 5 indexed citations
10.
Mahon, François-Xavier, Carla Boquimpani, Dong‐Wook Kim, et al.. (2018). Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase. Annals of Internal Medicine. 168(7). 461–470. 95 indexed citations
11.
Sticht, Carsten, Markus Pfirrmann, Daniel Nowak, et al.. (2017). The EUROSKI biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia. Annals of Oncology. 28. v367–v367. 1 indexed citations
12.
Mahon, François‐Xavier, Carla Boquimpani, Naoto Takahashi, et al.. (2016). Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood. 128(22). 1891–1891. 10 indexed citations
13.
Hughes, Timothy P., Carla Boquimpani, Naoto Takahashi, et al.. (2016). Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. Blood. 128(22). 792–792. 16 indexed citations
14.
Hughes, Timothy P., Carla Boquimpani, Dong‐Wook Kim, et al.. (2016). Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.. Journal of Clinical Oncology. 34(15_suppl). 7054–7054. 10 indexed citations
15.
Hehlmann, Rüdiger, Benjamin Hanfstein, Martin Müller, et al.. (2012). The prognostic significance of early molecular and cytogenetic response for long-term progression-free and overall survival in imatinib-treated chronic myeloid leukemia (CML).. Journal of Clinical Oncology. 30(15_suppl). 6510–6510. 3 indexed citations
16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carla Boquimpani Breakdown of academic impact, for papers by Franck E. Nicolini Breakdown of academic impact, for papers by Jeffrey Skinner Breakdown of academic impact, for papers by Susanne Jung-Munkwitz Breakdown of academic impact, for papers by Vasily Shuvaev Breakdown of academic impact, for papers by Alicia Enrico Breakdown of academic impact, for papers by Alex Allepuz Breakdown of academic impact, for papers by Ulrike Proetel Breakdown of academic impact, for papers by Nadine Pletsch Breakdown of academic impact, for papers by G Rosti
Rankless by CCL
2026